Wealth Architects LLC Maintains Position in GlaxoSmithKline PLC (GSK)

Wealth Architects LLC continued to hold its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,816 shares of the pharmaceutical company’s stock at the close of the second quarter. Wealth Architects LLC’s holdings in GlaxoSmithKline PLC were worth $207,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. lifted its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC lifted its stake in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares in the last quarter. Heritage Trust Co bought a new position in shares of GlaxoSmithKline PLC in the first quarter worth approximately $123,000. Finally, Westwood Holdings Group Inc. lifted its stake in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 9.29% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.themarketsdaily.com/2017/09/11/wealth-architects-llc-maintains-position-in-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline PLC (NYSE GSK) traded up 0.37% during midday trading on Monday, hitting $40.20. 2,378,175 shares of the stock traded hands. The stock has a 50-day moving average of $39.93 and a 200 day moving average of $41.82. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.53. The firm has a market cap of $98.25 billion, a PE ratio of 39.72 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts forecast that GlaxoSmithKline PLC will post $2.87 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a dividend yield of 4.90%. The ex-dividend date is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is 197.00%.

GSK has been the topic of several analyst reports. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. ValuEngine downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. GlaxoSmithKline PLC currently has an average rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply